SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-018692
Filing Date
2023-11-13
Accepted
2023-11-13 07:45:59
Documents
75
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q apge-20230930x10q.htm   iXBRL 10-Q 2014304
2 EX-10.7 apge-20230930xex10d7.htm EX-10.7 239838
3 EX-31.1 apge-20230930xex31d1.htm EX-31.1 13770
4 EX-31.2 apge-20230930xex31d2.htm EX-31.2 13806
5 EX-32.1 apge-20230930xex32d1.htm EX-32.1 12396
  Complete submission text file 0001558370-23-018692.txt   8050190

Data Files

Seq Description Document Type Size
6 EX-101.SCH apge-20230930.xsd EX-101.SCH 54851
7 EX-101.CAL apge-20230930_cal.xml EX-101.CAL 30473
8 EX-101.DEF apge-20230930_def.xml EX-101.DEF 243272
9 EX-101.LAB apge-20230930_lab.xml EX-101.LAB 442803
10 EX-101.PRE apge-20230930_pre.xml EX-101.PRE 396067
69 EXTRACTED XBRL INSTANCE DOCUMENT apge-20230930x10q_htm.xml XML 1148373
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

IRS No.: 880588063 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41740 | Film No.: 231395158
SIC: 2836 Biological Products, (No Diagnostic Substances)